FMP
NASDAQ
1.03 USD
-0.01 (-0.971%)
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Healthcare
Biotechnology
https://www.bionomics.com.au
NASDAQ
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a ...
0001191070
US09063M2052
09063M205
200 Greenhill Road
61 8 8354 6100
AU
8
Dec 16, 2021
0001191070
NASDAQ
Biotechnology
Healthcare
09063M205
US09063M2052
AU
1.03
-0.06
244.37k
11.58M
-
0.87-6.41
1.41
-
-
-
-
-0.44
-
https://www.bionomics.com.au
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.